These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 34082475)

  • 1. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection.
    Richter AG; Shields AM; Karim A; Birch D; Faustini SE; Steadman L; Ward K; Plant T; Reynolds G; Veenith T; Cunningham AF; Drayson MT; Wraith DC
    Clin Exp Immunol; 2021 Aug; 205(2):99-105. PubMed ID: 34082475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 infection as a trigger of autoimmune response.
    Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R
    Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes.
    Moody R; Sonda S; Johnston FH; Smith KJ; Stephens N; McPherson M; Flanagan KL; Plebanski M
    Front Immunol; 2022; 13():945021. PubMed ID: 36032086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population.
    Bichara CDA; da Silva Graça Amoras E; Vaz GL; da Silva Torres MK; Queiroz MAF; do Amaral IPC; Vallinoto IMVC; Bichara CNC; Vallinoto ACR
    BMC Infect Dis; 2021 May; 21(1):443. PubMed ID: 33992073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Prevalence of Interferon α Autoantibodies in People Experiencing Symptoms of Post-Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID.
    Peluso MJ; Mitchell A; Wang CY; Takahashi S; Hoh R; Tai V; Durstenfeld MS; Hsue PY; Kelly JD; Martin JN; Wilson MR; Greenhouse B; Deeks SG; DeRisi JL; Henrich TJ
    J Infect Dis; 2023 Jan; 227(2):246-250. PubMed ID: 36089700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals.
    Zhang J; Wu Q; Liu Z; Wang Q; Wu J; Hu Y; Bai T; Xie T; Huang M; Wu T; Peng D; Huang W; Jin K; Niu L; Guo W; Luo D; Lei D; Wu Z; Li G; Huang R; Lin Y; Xie X; He S; Deng Y; Liu J; Li W; Lu Z; Chen H; Zeng T; Luo Q; Li YP; Wang Y; Liu W; Qu X
    Nat Microbiol; 2021 Jan; 6(1):51-58. PubMed ID: 33199863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
    Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
    Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild Primary or Breakthrough SARS-CoV-2 Infection Promotes Autoantibody Production in Individuals with and without Neuro-PASC.
    Visvabharathy L; Dalil N; Leonor L; Zhu C; Orban ZS; Jimenez M; Lim PH; Penaloza-MacMaster P; Koralnik IJ
    Immunohorizons; 2024 Aug; 8(8):577-585. PubMed ID: 39186606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
    J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
    Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
    mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
    Aguilar-Bretones M; Westerhuis BM; Raadsen MP; de Bruin E; Chandler FD; Okba NM; Haagmans BL; Langerak T; Endeman H; van den Akker JP; Gommers DA; van Gorp EC; GeurtsvanKessel CH; de Vries RD; Fouchier RA; Rockx BH; Koopmans MP; van Nierop GP
    J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34499051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of viral load and antibody response in relation to COVID-19 severity.
    Wang Y; Zhang L; Sang L; Ye F; Ruan S; Zhong B; Song T; Alshukairi AN; Chen R; Zhang Z; Gan M; Zhu A; Huang Y; Luo L; Mok CKP; Al Gethamy MM; Tan H; Li Z; Huang X; Li F; Sun J; Zhang Y; Wen L; Li Y; Chen Z; Zhuang Z; Zhuo J; Chen C; Kuang L; Wang J; Lv H; Jiang Y; Li M; Lin Y; Deng Y; Tang L; Liang J; Huang J; Perlman S; Zhong N; Zhao J; Malik Peiris JS; Li Y; Zhao J
    J Clin Invest; 2020 Oct; 130(10):5235-5244. PubMed ID: 32634129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection.
    Chen C; Amelia A; Ashdown GW; Mueller I; Coussens AK; Eriksson EM
    Mol Med; 2021 Dec; 27(1):160. PubMed ID: 34930107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ACE2 autoantibodies after SARS-CoV-2 infection.
    Arthur JM; Forrest JC; Boehme KW; Kennedy JL; Owens S; Herzog C; Liu J; Harville TO
    PLoS One; 2021; 16(9):e0257016. PubMed ID: 34478478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals.
    Lingel H; Meltendorf S; Billing U; Thurm C; Vogel K; Majer C; Prätsch F; Roggenbuck D; Heuft HG; Hachenberg T; Feist E; Reinhold D; Brunner-Weinzierl MC
    J Autoimmun; 2021 Aug; 122():102682. PubMed ID: 34214763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.
    Peluso MJ; Deitchman AN; Torres L; Iyer NS; Munter SE; Nixon CC; Donatelli J; Thanh C; Takahashi S; Hakim J; Turcios K; Janson O; Hoh R; Tai V; Hernandez Y; Fehrman EA; Spinelli MA; Gandhi M; Trinh L; Wrin T; Petropoulos CJ; Aweeka FT; Rodriguez-Barraquer I; Kelly JD; Martin JN; Deeks SG; Greenhouse B; Rutishauser RL; Henrich TJ
    Cell Rep; 2021 Aug; 36(6):109518. PubMed ID: 34358460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins.
    Emmenegger M; Kumar SS; Emmenegger V; Malinauskas T; Buettner T; Rose L; Schierack P; Sprinzl MF; Sommer CJ; Lackner KJ; Aguzzi A; Roggenbuck D; Frauenknecht KBM
    PLoS Pathog; 2021 Dec; 17(12):e1010118. PubMed ID: 34860860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD).
    Gagiannis D; Steinestel J; Hackenbroch C; Schreiner B; Hannemann M; Bloch W; Umathum VG; Gebauer N; Rother C; Stahl M; Witte HM; Steinestel K
    Front Immunol; 2020; 11():587517. PubMed ID: 33123171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19
    Yuen RR; Steiner D; Pihl RMF; Chavez E; Olson A; Smith EL; Baird LA; Korkmaz F; Urick P; Sagar M; Berrigan JL; Gummuluru S; Corley RB; Quillen K; Belkina AC; Mostoslavsky G; Rifkin IR; Kataria Y; Cappione AJ; Gao W; Lin NH; Bhadelia N; Snyder-Cappione JE
    Front Immunol; 2021; 12():614676. PubMed ID: 33897682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients.
    Chen H; Zhang X; Liu W; Xue M; Liao C; Huang Z; Hu H; Sun B
    Int Immunopharmacol; 2021 Feb; 91():107325. PubMed ID: 33401205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.